NIOX Group (LON:NIOX) Stock: Insider Robert (Rob) Graham Naylor Sells 1,639 Shares

Key Points

• Insider Robert (Rob) Graham Naylor sold 1,639 NIOX Group shares on October 27 at an average price of GBX 80, for total proceeds of £1,311.20.
• NIOX shares rose 0.3% to GBX 64.60 in Wednesday mid-day trading, with a market capitalization of about £271.9 million.
• The company reported quarterly earnings of GBX 1.41 per share; analysts expect full-year earnings of GBX 1.17 per share.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Robert (Rob) Graham Naylor sold 1,639 shares of the business's stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of GBX 80, for a total transaction of £1,311.20.

NIOX Group Trading Up 0.3%

Shares of LON NIOX traded up GBX 0.20 during mid-day trading on Wednesday, reaching GBX 64.60. The company had a trading volume of 281,066 shares, compared to its average volume of 902,221. The stock has a market cap of £271.88 million, a price-to-earnings ratio of 39.63 and a beta of 0.92. NIOX Group Plc has a 52 week low of GBX 53.84 and a 52 week high of GBX 80. The business's 50-day moving average is GBX 67.34 and its 200-day moving average is GBX 63.13. The company has a current ratio of 4.60, a quick ratio of 1.94 and a debt-to-equity ratio of 1.06.

NIOX Group (LON:NIOX - Get Free Report) last announced its quarterly earnings data on Wednesday, September 30th. The company reported GBX 1.41 earnings per share for the quarter. NIOX Group had a net margin of 14.74% and a return on equity of 10.01%. Equities analysts expect that NIOX Group Plc will post 1.17 earnings per share for the current year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.